Molecule Discovered That Converts Stem Cells Into Heart Cells
For years, scientists have been looking for a good source of heart cells that can be used to study cardiac function in the lab, or perhaps even to replace diseased or damaged tissue in heart disease patients. To do this, many are looking to stem cells. Researchers at Sanford-Burnham Medical Research Institute (Sanford-Burnham), the Human BioMolecular Research Institute, and ChemRegen, Inc. have been searching for molecules that convert stem cells to heart cells for about eight years – and now they’ve found one. Writing in Cell Stem Cell, the team describes how they sifted through a large collection of drug-like chemicals and uncovered ITD-1, a molecule that can be used to generate unlimited numbers of new heart cells from stem cells.
“Heart disease is the leading cause of death in this country. Because we can’t replace lost cardiac muscle, the condition irreversibly leads to a decline in heart function and ultimately death. The only way to effectively replace lost heart muscle cells – called cardiomyocytes – is to transplant the entire heart,” said Mark Mercola, Ph.D., director of Sanford-Burnham’s Muscle Development and Regeneration Program and senior author of the study. “Using a drug to create new heart muscle from stem cells would be far more appealing than heart transplantation.”
Searching for a needle in a haystack
Stem cells are important because they do two unique things – 1) self-renew, producing more stem cells and 2) differentiate, becoming other, more specialized cell types. To obtain a large number of a certain cell type, such as heart cells, the hard part is figuring out the signals that direct them to become the desired cell type.
Mercola’s group has been hunting for heart-inducing signals for 15 years – in embryos and in stem cells. To find a synthetic molecule that might one day lead to a drug therapy to regenerate the heart, they joined forces with a team of medicinal chemists at the Human BioMolecular Research Institute led by John Cashman, Ph.D. With funding from the California Institute for Regenerative Medicine, they used sophisticated robotic technology to methodically test a large collection of drug-like chemicals, looking for that needle in a haystack that, when added to stem cells, results in cardiomyocytes. The winning compound was ITD-1.
There’s no shortage of therapeutic possibilities for ITD-1. “This particular molecule could be useful to enhance stem cell differentiation in a damaged heart,” explained Erik Willems, Ph.D., postdoctoral researcher in Mercola’s lab and first author of the study. “At some point, it could become the basis for a new therapeutic drug for cardiovascular disease – one that would likely limit scar spreading in heart failure and promote new muscle formation.”
Mercola, Willems, and Cashman are now working with San Diego biotech company ChemRegen, Inc. to further develop ITD-1 into a drug that one day might be used to treat patients.
More scientific detail
The researchers discovered that ITD-1 blocks a cellular process known as TGFϐ signaling. TGFϐ (short for transforming growth factor-ϐ) is a protein produced by one cell type to influence others’ behaviors, such as proliferation, scarring, and even stem cell differentiation. TGFϐ works from outside the cell, binding to a receptor on the surface of a responding cell to initiate an intracellular signaling cascade that causes genes to be switched on or off, ultimately altering cellular behavior – in this case making heart muscle.
ITD-1 triggers degradation of the TGFϐ receptor, thus inhibiting the whole process. With TGFϐ signaling turned off, stem cells are set on a course toward cardiogenesis. ITD-1 is the first selective inhibitor of TGFϐ, meaning that it might also have applications in many other processes controlled by TGFϐ.
Tuberclosis(TB) being the infectious disease is communicated almost exclusively by coughed aerosols carrying pathogens of Mycobacterium tuberclosis (Mtb). As reported by World Health Organization (WHO) it causes disease in 9.6 millions people each year and ranks with human immunodeficiency virus (HIV) as a leading cause of disease. A well timed diagnosis and appropriate treatment can […]Read More »
A researcher at Moffitt Cancer Center and his international team of colleagues have reported study results on a novel multireceptor-targeted somatostatin analogue called pasireotide (SOM230) manufactured by Novartis Pharma AG. The Phase II, open-label, multicenter study in patients with advanced neuroendocrine tumors (NET) whose symptoms were no longer responsive to octreotide LAR therapy found that […]Read More »
In a large epidemiologic study, researchers at UCLA’s Jonsson Cancer Center found that the children of U.S.-born Latina women are at higher risk of having retinoblastoma, a malignant tumor of the retina which typically occurs in children under six. The study, which focused on babies born in California, also found that offspring of older fathers […]Read More »
Since June 2012, it is official: The World Health Organisation (WHO) has classified diesel soot as a lung carcinogen. Artur Braun, a physicist at Empa and an X-ray spectroscopy expert, has made crucial contributions to analyzing the structure and composition of soot particles. Soot particles are dangerous – there is nothing new in this knowledge. […]Read More »
A new clinical trial published in the August edition of Clinical Cancer Research has revealed that cancer patients who drink one glass of grapefruit juice per day achieve the same benefits from an anti-cancer drug as they would get from more than three times as much of the drug by itself. It could also help […]Read More »
On 14 February 2012, the German Institute for Quality and Efficiency in Health Care (IQWiG) published the results of a literature search for evidence-based clinical practice guidelines on the treatment of people with heart failure. The aim of the report is to identify those recommendations from current guidelines of high methodological quality that may be […]Read More »
When combined with standard diagnostic tests, functional imaging procedures have been shown to reduce the rate of misdiagnosed cases of infectious endocarditis. According to new research published in the August issue of The Journal of Nuclear Medicine, single photon emission computed tomography (SPECT)/computed tomography (CT) with 99mTc-hexamethylpropleneamine oxime-labeled white blood cells (99mTc-HMPAO-WBC) can improve the […]Read More »
For years, scientists have been looking for a good source of heart cells that can be used to study cardiac function in the lab, or perhaps even to replace diseased or damaged tissue in heart disease patients. To do this, many are looking to stem cells. Researchers at Sanford-Burnham Medical Research Institute (Sanford-Burnham), the Human […]Read More »
A new genetic analysis focusing on Jews from North Africa has provided an overall genetic map of the Jewish Diasporas. The findings support the historical record of Middle Eastern Jews settling in North Africa during Classical Antiquity, proselytizing and marrying local populations, and, in the process, forming distinct populations that stayed largely intact for more […]Read More »
University of Minnesota School of Public Health researchers have found that medical group practices can reduce costs for patients with diabetes by investing in improved quality of care. In the study, which appears in the August issue of Health Affairs, University of Minnesota researchers analyzed 234 medical group practices providing care for more than 133,000 […]Read More »